{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:23:57Z","timestamp":1792567437835,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T00:00:00Z","timestamp":1272585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once-yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multicenter, double-blind, active-controlled, parallel-group study, participants (n\u2009=\u2009302) were randomized to receive either once-yearly ZOL 5\u2009mg i.v. or weekly oral ALN 70\u2009mg for 24 months. Changes in BMD and bone marker levels were assessed. ZOL increased BMD at the lumbar spine, total hip, femoral neck, and trochanter and was not inferior to ALN at 24 months [least squares mean estimates of the percentage increases in lumbar spine BMD of 6.1% and 6.2%; difference approximately 0.13; 95% confidence interval (CI) 1.12\u20130.85 in the ZOL and ALN groups, respectively]. At month 12, the median change from baseline of markers for bone resorption [serum \u03b2-C-terminal telopeptide of type I collagen (\u03b2-CTx) and urine N-terminal telopeptide of type I collagen (NTx)] and formation [serum N-terminal propeptide of type I collagen (P1NP) and serum bone-specific alkaline phosphatase (BSAP)] were comparable between ZOL and ALN groups. Most men preferred i.v. ZOL over oral ALN. The incidence of adverse events and serious adverse events was similar in the treatment groups. It is concluded that a once-yearly i.v. infusion of ZOL 5\u2009mg increased bone density and decreased bone turnover markers similarly to once-weekly oral ALN 70\u2009mg in men with low bone density. \u00a9 2010 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.119","type":"journal-article","created":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T14:43:11Z","timestamp":1272724991000},"page":"2239-2250","source":"Crossref","is-referenced-by-count":159,"title":["Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5\u2009mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study"],"prefix":"10.1093","volume":"25","author":[{"given":"Eric S","family":"Orwoll","sequence":"first","affiliation":[{"name":"Oregon Health Sciences University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D","family":"Miller","sequence":"additional","affiliation":[{"name":"School of Medicine, Colorado Center for Bone Research, Lakewood, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Bheumatology, Centre Hospitalier Universitaire de Qu\u00e9bec, Sainte-Foy, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Adler","sequence":"additional","affiliation":[{"name":"Endocrinology, McGuire Veterans Affairs Medical Center, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kendler","sequence":"additional","affiliation":[{"name":"Prohealth Clinical Research, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bucci-Rechtweg","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Readie","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mesenbrink","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Department of Medicine, Central Arkansas Veterans Healthcare System, University of Arkansas for Medical Sciences, Little Rock, AR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,4,30]]},"reference":[{"key":"2024020320094919600_bib1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med."},{"key":"2024020320094919600_bib2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures","volume":"18","author":"Cummings","year":"2002","journal-title":"Lancet."},{"key":"2024020320094919600_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/B978-012470862-4\/50022-2","volume-title":"Osteoporosis","author":"Melton","year":"2001","edition":"2nd ed"},{"key":"2024020320094919600_bib4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1590\/S0004-27302006000400021","article-title":"Osteoporosis in men","volume":"50","author":"Binkley","year":"2006","journal-title":"Arq Bras Endocrinol Metab."},{"key":"2024020320094919600_bib5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00002512-200522090-00003","article-title":"Male osteoporosis: new trends in diagnosis and therapy","volume":"22","author":"Kamel","year":"2005","journal-title":"Drugs Aging."},{"key":"2024020320094919600_bib6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet."},{"key":"2024020320094919600_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/PL00004182","article-title":"Effects of alendronate on bone density in men with primary and secondary osteoporosis","volume":"11","author":"Ho","year":"2000","journal-title":"Osteoporos Int."},{"key":"2024020320094919600_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00223-001-1066-2","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"69","author":"Adami","year":"2001","journal-title":"Calcif Tissue Int."},{"key":"2024020320094919600_bib9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/meta.2001.24925","article-title":"Effect of alendronate on bone mineral density in male idiopathic osteoporosis","volume":"50","author":"Weber","year":"2001","journal-title":"Metabolism."},{"key":"2024020320094919600_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00223-002-1085-7","article-title":"Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study","volume":"73","author":"Gonnelli","year":"2003","journal-title":"Calcif Tissue Int."},{"key":"2024020320094919600_bib11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"J Bone Miner Res."},{"key":"2024020320094919600_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"HORIZON Pivotal Fracture Trial Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"358","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"2024020320094919600_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone."},{"key":"2024020320094919600_bib14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2214\/ajr.183.4.1830949","article-title":"Diagnosis of osteoporotic vertebral fractures: importance of recognition and description by radiologists","volume":"R183","author":"Lenchik","year":"2004","journal-title":"AJR Am J Roentgenol."},{"key":"2024020320094919600_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1359\/jbmr.071019","article-title":"Factors affecting short-term bone density precision assessment and the effect on patient monitoring","volume":"23","author":"Leslie","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024020320094919600_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00198-006-0280-1","article-title":"A study of the long-term precision of dual-energy X-ray absorptiometry bone densitometers and implications for the validity of the least-significant-change calculation","volume":"18","author":"Hangartner","year":"2007","journal-title":"Osteoporos Int."},{"key":"2024020320094919600_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00198-003-1409-0","article-title":"Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate","volume":"14","author":"Christiansen","year":"2003","journal-title":"Osteoporos Int."},{"key":"2024020320094919600_bib18","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med."},{"key":"2024020320094919600_bib19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2008.193","article-title":"Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women","volume":"74","author":"Boonen","year":"2008","journal-title":"Kidney Int."},{"key":"2024020320094919600_bib20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.clinthera.2009.05.001","article-title":"Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers","volume":"31","author":"Rhim","year":"2009","journal-title":"Clinical Therapeutics."},{"key":"2024020320094919600_bib21","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/BF01623002","article-title":"Clinical Pharmacology of Alendronate Sodium B","volume":"3","author":"Gertz","year":"1993","journal-title":"Osteoporosis Int Suppl."},{"key":"2024020320094919600_bib22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/01.bco.0000141919.24040.91","article-title":"Bisphosphonates: a practical guide","volume":"15","author":"Bukata","year":"2004","journal-title":"Curr Opin Orthop."},{"key":"2024020320094919600_bib23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","article-title":"Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis","volume":"21","author":"Cramer","year":"2005","journal-title":"Curr Med Res Opin."},{"key":"2024020320094919600_bib24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clinic Proceedings."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.119","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/25\/10\/2239\/56577470\/jbmr119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/25\/10\/2239\/56577470\/jbmr119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:45:25Z","timestamp":1710341125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/25\/10\/2239-2250\/7600116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,30]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2010,4,30]]},"published-print":{"date-parts":[[2010,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.119","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,10,1]]},"published":{"date-parts":[[2010,4,30]]}}}